Id |
Subject |
Object |
Predicate |
Lexical cue |
T127 |
0-111 |
Sentence |
denotes |
Several anticytokine therapies have been tried for treating the hyperinflammatory phase of COVID-19 [20,23–25]. |
T128 |
112-239 |
Sentence |
denotes |
Here, we report the use of a well-known anti-inflammatory antibody targeting CD6 to treat the CRS arising in COVID-19 patients. |
T129 |
240-471 |
Sentence |
denotes |
Using an anti-CD6 antibody could reduce the concentration of several pro-inflammatory cytokines, including IL-6, IFN-γ, TNF-α and IL-17, among others, representing an advantage as compared with single-cytokine targeting antibodies. |
T130 |
472-597 |
Sentence |
denotes |
The antibody would not exacerbate lymphopenia since it does not induce complement or antibody dependent cytotoxicity [10,11]. |